• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

QTc间期延长作为转甲状腺素蛋白心脏淀粉样变疾病分期的标志物。

QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis.

作者信息

Tsampras Theodoros, Antonopoulos Alexios S, Kourti Freideriki-Eleni, Tsioufis Konstantinos, Vlachopoulos Charalambos

机构信息

Cardiogenetics Unit, 1 st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, 114 Vas. Sofias Avenue, Athens, Greece.

出版信息

Clin Res Cardiol. 2025 Jul 3. doi: 10.1007/s00392-025-02680-x.

DOI:10.1007/s00392-025-02680-x
PMID:40608076
Abstract

Transthyretin amyloidosis is a significant cause of heart failure with an unfavorable prognosis. In recent years, diagnosing the disease has become easier, with most patients now diagnosed non-invasively, and tissue biopsy being required only in a minority of cases. Although various laboratory findings have been reported as transthyretin amyloidosis red flags, the diagnostic and prognostic value of various electrocardiogram parameters remain largely unknown. In this study, the significance of QTc interval prolongation in transthyretin cardiac amyloidosis patients was investigated. We retrospectively analyzed electrocardiogram data from n = 58 patients with transthyretin amyloid cardiomyopathy and compared them with distinct cohorts of patients diagnosed with other forms of heart muscle disease, i.e., hypertrophic cardiomyopathy and dilated cardiomyopathy. QTc prolongation was found to be a unique feature of transthyretin cardiac amyloidosis, not shared by other cardiomyopathy types. Increased QTc interval in transthyretin amyloidosis patients correlates with disease severity markers, including NYHA class, NAC stage, NT-proBNP, and troponin I levels, suggesting its potential as a unique biomarker for monitoring disease progression.

摘要

转甲状腺素蛋白淀粉样变性是导致心力衰竭的一个重要原因,预后不佳。近年来,该病的诊断变得更加容易,现在大多数患者通过非侵入性方法即可确诊,仅少数病例需要进行组织活检。尽管已有各种实验室检查结果被报道为转甲状腺素蛋白淀粉样变性的警示信号,但各种心电图参数的诊断和预后价值在很大程度上仍不明确。在本研究中,我们调查了QTc间期延长在转甲状腺素蛋白心脏淀粉样变性患者中的意义。我们回顾性分析了n = 58例转甲状腺素蛋白淀粉样心肌病患者的心电图数据,并将其与诊断为其他形式心肌病(即肥厚型心肌病和扩张型心肌病)的不同患者队列进行比较。结果发现QTc延长是转甲状腺素蛋白心脏淀粉样变性的一个独特特征,其他类型的心肌病并不具备。转甲状腺素蛋白淀粉样变性患者QTc间期增加与疾病严重程度指标相关,包括纽约心脏协会(NYHA)心功能分级、NAC分期、N末端脑钠肽前体(NT-proBNP)和肌钙蛋白I水平,这表明其有可能作为监测疾病进展的独特生物标志物。

相似文献

1
QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis.QTc间期延长作为转甲状腺素蛋白心脏淀粉样变疾病分期的标志物。
Clin Res Cardiol. 2025 Jul 3. doi: 10.1007/s00392-025-02680-x.
2
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Isolated Methylmalonic Acidemia孤立性甲基丙二酸血症
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
8
Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.野生型转甲状腺素蛋白淀粉样心肌病的疑诊、筛查和诊断:系统文献回顾。
ESC Heart Fail. 2022 Jun;9(3):1524-1541. doi: 10.1002/ehf2.13884. Epub 2022 Mar 27.
9
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.生物标志物对改良心脏风险指数在预测非心脏手术患者主要不良心脏事件和全因死亡率方面的比较和附加预后价值。
Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD013139. doi: 10.1002/14651858.CD013139.pub2.
10
A Challenging Case of Wild-Type Transthyretin Amyloidosis (ATTR) Amyloidosis Treated With Cardiac Resynchronization Therapy.1例具有挑战性的野生型转甲状腺素蛋白淀粉样变性(ATTR)淀粉样变性病例采用心脏再同步治疗。
Cureus. 2025 Jul 2;17(7):e87203. doi: 10.7759/cureus.87203. eCollection 2025 Jul.

本文引用的文献

1
A phenomap of TTR amyloidosis to aid diagnostic screening.用于辅助诊断筛查的转甲状腺素蛋白淀粉样变性病表型图谱。
ESC Heart Fail. 2025 Apr;12(2):1113-1118. doi: 10.1002/ehf2.15143. Epub 2024 Oct 31.
2
Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral Center.希腊转甲状腺素蛋白淀粉样变性心肌病:来自国家转诊中心的临床见解。
Hellenic J Cardiol. 2024 Sep-Oct;79:25-34. doi: 10.1016/j.hjc.2023.09.019. Epub 2023 Oct 5.
3
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.
2023年美国心脏病学会关于心脏淀粉样变性患者综合多学科护理的专家共识决策路径:美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. doi: 10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23.
4
Cardiac amyloidosis remains significantly underdiagnosed in patients undergoing TAVR: analysis of National Inpatient Sample.心脏淀粉样变性在接受经导管主动脉瓣置换术(TAVR)的患者中仍存在严重漏诊情况:基于全国住院患者样本的分析
Amyloid. 2023 Jun;30(2):246-247. doi: 10.1080/13506129.2022.2159369. Epub 2022 Dec 21.
5
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.转甲状腺素蛋白淀粉样变性的患病率及临床结局:一项系统评价和荟萃分析。
Eur J Heart Fail. 2022 Sep;24(9):1677-1696. doi: 10.1002/ejhf.2589. Epub 2022 Aug 2.
6
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗:欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
7
Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).心脏淀粉样变性的诊断和治疗:德国心脏病学会(DGK)立场声明。
Clin Res Cardiol. 2021 Apr;110(4):479-506. doi: 10.1007/s00392-020-01799-3. Epub 2021 Jan 18.
8
Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis.心电图参数与心脏轻链淀粉样变性患者左心室纵向应变及预后的相关性。
Sci Rep. 2019 May 23;9(1):7746. doi: 10.1038/s41598-019-44245-9.
9
Corrected QT in ventricular paced rhythms: what is the validation for commonly practiced assumptions?心室起搏心律下的校正QT:常用假设的验证是什么?
Cardiology. 2015;130(4):207-10. doi: 10.1159/000370026. Epub 2015 Mar 12.
10
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.遗传性转甲状腺素蛋白相关淀粉样变性病仅有心脏表型的疾病特征和鉴别诊断:意大利视角。
Eur Heart J. 2013 Feb;34(7):520-8. doi: 10.1093/eurheartj/ehs123. Epub 2012 Jun 28.